Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

Phase 2

Completed

Conditions: Breast Ductal Carcinoma In Situ

Interventions: Other: Laboratory Biomarker Analysis
Drug: Nelipepimut-S Plus GM-CSF Vaccine
Biological: Sargramostim
Procedure: Surgical Procedure

Registration Number: NCT02636582

Lead Sponsor: National Cancer Institute (NCI)

Brief Summary: This phase II trial studies how well nelipepimut-S plus GM-CSF vaccine therapy or sargramostim works in treating patients with breast cancer. Vaccines made from peptide or antigen and/or a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells that express breast cancer antigens. It is not yet known whether nelipepimut-S plus GM-CSF vaccine or sargramostim is more effective in treating patients with breast cancer.

Detailed Description: PRIMARY OBJECTIVE:

I. Evaluate for nelipepimut-S-specific cytotoxic T lymphocyte (CTL; cluster of differentiation \[CD\]8+ T cell) response in patients receiving NeuVax (nelipepimut-S plus GM-CSF \[sargramostim\]) compared to patients receiving GM-CSF alone (control).

SECONDARY OBJECTIVES:

I. Toxicity profile and frequency of adverse events in women with ductal carcinoma in situ (DCIS) of the breast receiving nelipepimut-S vaccine as compared to women receiving GM-CSF alone.

II. Presence of DCIS at resection. III. Difference in HER2 expression in the biopsy and the surgical specimen excised post-vaccination.

IV. Histologic responses:

IVa. Degree of lymphocyte infiltration determined on hematoxylin and eosin (H\&E) stained slides and immune infiltration as determined by multiplex immunofluorescence staining for markers including but not limited to CD3, CD4 and CD8.

IVb. Immune infiltrates in normal tissue maximally distant from the tumor (in mastectomy samples).

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive nelipepimut-S plus GM-CSF vaccine intradermally (ID) on days 0 and 14 and then undergo surgery on day 28.

ARM II: Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.

After completion of study treatment, patients are followed up at 1 and 3 months.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 43

Inclusion Criteria

Participants must be pre- or post-menopausal
Participants must have a diagnosis of DCIS made by core needle biopsy
Participants must be human leukocyte antigen (HLA)-A2 positive
Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1 (Karnofsky >= 60%)
Clinical chemistry less than 2 x normal upper limit of normal range
Platelets >= 100,000/mm^3
Hemoglobin >= 10 g/dL
Blood urea nitrogen < 2 x upper limit of normal (ULN)
Alkaline phosphatase < 2 x ULN
Lactate dehydrogenase < 2 x ULN
Creatinine < 2 x ULN
Bilirubin < 2 x ULN
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2 x ULN
A normal ejection fraction, as defined by the participant's institution; only limited echocardiograms (ECHOs) will be used as cardiac evaluation; no other tests are allowed; ECHO is to be done only in HLA-A2 positive participants; if ECHO has been done within 30 days prior to randomization and results showing a normal ejection fraction have been obtained prior to randomization, an additional ECHO is not needed at baseline
Willingness to comply with all study interventions and follow-up procedures
The ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

Invasive breast cancer; areas of microinvasion or suspicious for microinvasion on the core biopsy is allowed
History of prior breast cancer treated within the past two years; patients completing all breast cancer-specific treatment over two years prior to the current diagnosis are eligible
History of prior ductal carcinoma in situ (DCIS) treated within the past two years; patients completing all treatment for a previous diagnosis of DCIS over two years prior to the current diagnosis are eligible
Prior lobular carcinoma in situ (LCIS) is allowed
Pregnant, unwilling to use adequate contraception during study treatment duration or breastfeeding; the effects of NeuVax on the developing human fetus are unknown; for this reason and because NeuVax may be teratogenic, pregnant women will be excluded; all heterosexually active women who may become pregnant must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation OR be post-menopausal defined as any one of the following 1) prior hysterectomy, 2) absence of menstrual period for 1 year in the absence of prior chemotherapy or 3) absence of menstrual period for 2 years in women with a prior history of chemotherapy exposure who were pre-menopausal prior to chemotherapy; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
Any autoimmune disease or other medical condition that, in the opinion of the investigator, would compromise the subject's safety
Immune deficiency diseases such as immunoglobulin deficiency or immunosuppressive therapy that might interfere with appropriate immune response
Known history of or known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Patients on chronic steroid therapy or other immunosuppressive therapy except for topical or inhaled steroids known to have low systemic absorption
Patients with a known hypersensitivity to GM-CSF, yeast-derived products, or any component of the GM-CSF product (e.g., mannitol)
Concurrent treatment with other investigational agent
History of non-breast malignancy within 5 years prior to randomization, except curatively treated superficial bladder cancer, carcinoma in situ of the cervix (stage 0-1), and basal cell or squamous cell carcinoma of the skin
History of allergic reactions attributed to compounds of similar chemical or biologic composition to NeuVax
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
No recent or planned immunotherapy

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm I (nelipepimut-S plus GM-CSF vaccine)	Nelipepimut-S Plus GM-CSF Vaccine	Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
Arm II (sargramostim)	Laboratory Biomarker Analysis	Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
Arm II (sargramostim)	Surgical Procedure	Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
Arm I (nelipepimut-S plus GM-CSF vaccine)	Laboratory Biomarker Analysis	Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.
Arm II (sargramostim)	Sargramostim	Patients receive sargramostim ID on days 0 and 14 and then undergo surgery on day 28.
Arm I (nelipepimut-S plus GM-CSF vaccine)	Surgical Procedure	Patients receive nelipepimut-S plus GM-CSF vaccine ID on days 0 and 14 and then undergo surgery on day 28.

Primary Outcome Measures

Name	Time	Method
Mean Percent of Nelipepimut-S-specific Cytotoxic T Lymphocyte Response (E75)	One-Month post-surgical resection from baseline	Change from baseline in the Mean percent of Nelipepimut-S-specific cytotoxic T lymphocyte response one-month post-surgical resection. Wilcoxon rank sum test exact P-value was used.

Secondary Outcome Measures

Name	Time	Method
Number of Participants With Presence of Ductal Carcinoma in Situ (DCIS)	At resection	Presence of DCIS with Invasive Cancer.
Number of Participants With HER2 Expression in Biopsy and Resection Specimens	Baseline to surgical resection, up to 5 weeks	Difference in HER2 Expression in Biopsy and Resection Specimens. Differences were assessed using a Fisher's exact test.
Intra-tumoral Tumor-infiltrating Lymphocytes (iTILs) Within the Basement Membrane	Baseline to surgical resection, up to 5 weeks	Change from baseline in the iTILs at surgical resection. Wilcoxon rank sum test exact P-value was used.
Intra-tumoral Tumor-infiltrating Lymphocytes (iTILs)	Baseline to surgical resection, up to 5 weeks	Change from baseline in the iTILs at surgical resection. Wilcoxon rank sum test exact P-value was used.
Number of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03	3-6 months after surgery	The number of serious and non serious adverse events for both arms. Graded According to national Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 4.03.

Trial Locations

Locations (4): Thomas Jefferson University Hospital
🇺🇸
Philadelphia, Pennsylvania, United States
Dana-Farber Cancer Institute
🇺🇸
Boston, Massachusetts, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
🇺🇸
New York, New York, United States
M D Anderson Cancer Center
🇺🇸
Houston, Texas, United States